TBRG(Delisted)
Stock Fundamental
Valuation5.5/10
NeutralKey Valuation Metric
PE Method: TBRG's market cap is approximately 393.58M with TTM earnings of 440.40M, corresponding to a PE ratio of 89.4. Compared to the Health Care Technology industry average, this valuation may be overvalued.
PS Method: TBRG's market cap is approximately 393.58M with a PS ratio of 1.1. Compared to the Health Care Technology industry average, this valuation may be undervalued.
PEG Method: With a PE of 89.4 and forward PE of 89.4, the PEG ratio comes to 1.00, indicating a reasonable valuation.
Historical Price to Earnings Ratio
Historical data shows that TBRG's P/E reached a peak of about 89.40 on 2026-07-06, and a trough of about -222.83 on 2023-11-14. The current P/E is 89.37, which places it at approximately the 100% percentile of its historical range, indicating a relatively overvalued valuation.
Share Price vs Future Cash Flow Value
TBRG's current stock price is about $26.24, while its Discounted Cash Flow valuation is about $16.22. Based on the Discounted Cash Flow model, the market price represents a premium over its intrinsic value.
Future Growth5.3/10
NeutralEarnings and Revenue Growth Forecasts
TBRG's Revenue moved from about 85.60M (2024) to about 86.27M (2026) in recent actuals. Analyst forecasts include about 87.29M, 87.45M, and 87.62M for the next forecast periods, implying an overall 3-year CAGR of roughly 0.5% versus the latest actual—indicating a fluctuating trend in Revenue..
Future Return on Equity
Analysts predict TBRG's future return on equity (Future ROE) will be about 0.9% over the next three years, higher than the Health Care Technology industry average of -45.6%, indicating its leading position in capital profitability. A higher Future ROE generally reflects stronger expected profitability on shareholder equity, subject to business risk and accounting differences.
Past Performance5.6/10
NeutralRevenue & Expenses Breakdown
TBRG's revenue primarily comes from Financial Health, Patient Care, — and —. Among these, Financial Health accounts for 63.9%; Patient Care for 36.1%, — for 0.0% and — for 0.0%. The company's main business is relatively concentrated.
Earnings & Revenue
- Earnings per share (TTM)0.60
- Gross margin55.55%
- Net profit margin0.59%
- Debt / equity1.28x
The company's earnings quality is weaker. Net profit for the latest fiscal period is about 506.00K, while free cash flow is estimated at 9.28M. The 8.77M difference between the two indicates significant cash conversion capabilities. suggesting a meaningful gap between accounting earnings and cash generation, often driven by non-cash items or working capital.
Free Cash Flow vs Earnings Analysis
TBRG's net income is about 6.63M, while free cash flow is about 9.28M, representing a FCF/Earnings ratio of 140.0%. The conversion from earnings to free cash flow is efficient, indicating strong cash generation relative to book earnings.
Financial Health5.2/10
NeutralDebt to Equity History and Analysis
In 2026-03, total liabilities (Debt) are about 228.85M; total equity (Equity) is about 178.69M. These figures come from the financial health diagnose series (debt / equity). They describe capital structure, not operating earnings.
Balance Sheet
Assets
Liabilities + Equity
The company's shareholders' equity is $178.69M, representing about 43.8% of total assets, while total debt is $167.35M, representing about 41.1% of total assets. This low-leverage structure means expansion relies primarily on profits and equity capital, resulting in lower financial risk.
Dividends4.0/10
NeutralStability and Growth of Payments
TBRG is not paying a notable dividend in the U.S. market context; detailed stability and growth checks are less relevant until distributions become material.
Dividend Yield vs Market
TBRG's current dividend yield is 0.00%, while the Health Care Technology industry average is around 1.65%. The top 25% of companies in the entire US market have a dividend yield of 2.21%, while the bottom 25% have a yield of 1.10%. In comparison, TBRG is clearly at the bottom of the industry.
Earnings Payout to Shareholders
Earnings coverage: TBRG is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash flow coverage: TBRG is not paying a notable dividend for the US market.
- Based on a composite score of 3.65/10, we rate TBRG as a Netural. Our analysis breaks down into 9.09/10 for Fundamentals, 2.29/10 for Technicals, and 3.85/10 for Sentiment, indicating the stock is likely to consolidate sideways.
- Based on a composite score of 3.65/10, we rate TBRG as a Netural. Our analysis breaks down into 9.09/10 for Fundamentals, 2.29/10 for Technicals, and 3.85/10 for Sentiment, indicating the stock is likely to consolidate sideways.
